Febrile Neutropenia Market to Witness Growth by 2032, Estimates DelveInsight | Key Companies – Spectrum Pharmaceuticals (ROLVEDON (eflapegrastim-xnst)), Fresenius Kabi (Stimufend (pegfilgrastim-fpgk))

 Breaking News
  • No posts were found

Febrile Neutropenia Market to Witness Growth by 2032, Estimates DelveInsight | Key Companies – Spectrum Pharmaceuticals (ROLVEDON (eflapegrastim-xnst)), Fresenius Kabi (Stimufend (pegfilgrastim-fpgk))

September 17
07:20 2022
Febrile Neutropenia Market to Witness Growth by 2032, Estimates DelveInsight | Key Companies - Spectrum Pharmaceuticals (ROLVEDON (eflapegrastim-xnst)), Fresenius Kabi (Stimufend (pegfilgrastim-fpgk))
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 10+ key pharma and biotech companies are working in the Febrile Neutropenia therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

DelveInsight’s “Febrile Neutropenia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Febrile Neutropenia Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Febrile Neutropenia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Febrile Neutropenia Market

Febrile Neutropenia: An Overview

Febrile Neutropenia is the most common serious and common complication of cancer therapy. Neutropenic fever is the most common and serious complication associated with hematopoietic cancers or with patients receiving chemotherapeutic regimens for cancer. Neutropenic fever occurs when a neutropenic patient encounters an infectious pathogen.

Neutropenic fever is defined as a single oral temperature greater than or equal to 101 F, or a temperature greater than or equal to 100.4 F for at least an hour, with an absolute neutrophilic count (ANC) of less than 1500 cells/microliter. In severe neutropenia, the absolute neutrophil count (ANC) is less than 500 per microliter, or ANC is expected to decrease below 500 cells/microL in the next 2 hours.

Febrile Neutropenia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Febrile Neutropenia market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report details the Febrile Neutropenia market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Febrile Neutropenia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Febrile Neutropenia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Febrile Neutropenia market or expected to get launched during the study period. The analysis covers Febrile Neutropenia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Febrile Neutropenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Key Developments in the Febrile Neutropenia Therapeutics Market

• On September 09, 2022, Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) announced that the U.S. FDA has approved ROLVEDON™ (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

• On September 06, 2022, Fresenius Kabi announced that the U.S. FDA had approved its biosimilar, Stimufend® (pegfilgrastim-fpgk), for use in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Learn how the Febrile Neutropenia Market will evolve in the coming years:
https://www.delveinsight.com/sample-request/febrile-neutropenia-market

Febrile Neutropenia Therapeutics Analysis

There are approx. 10+ key companies which are developing the therapies Febrile Neutropenia. Currently, Daewoong Pharmaceutical has its Febrile Neutropenia drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Febrile Neutropenia Therapeutic Market include:

• Daewoong Pharmaceutical

• RedHill Biopharma

• Allakos

• Hanmi Pharmaceutical

• Trio Medicines

• Bristol-Myers Squibb

And many others

Febrile Neutropenia Emerging Drugs Covered in the report include:

Plinabulin: BeyondSpring Pharmaceuticals

And many more

Further product details are provided in the report. Download the sample Report to get more detailed insights at:
https://www.delveinsight.com/sample-request/febrile-neutropenia-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Febrile Neutropenia Competitive Intelligence Analysis

4. Febrile Neutropenia Market Overview at a Glance

5. Febrile Neutropenia Disease Background and Overview

6. Febrile Neutropenia Patient Journey

7. Febrile Neutropenia Epidemiology and Patient Population

8. Febrile Neutropenia Treatment Algorithm, Current Treatment, and Medical Practices

9. Febrile Neutropenia Unmet Needs

10. Key Endpoints of Febrile Neutropenia Treatment

11. Febrile Neutropenia Marketed Products

12. Febrile Neutropenia Emerging Therapies

13. Febrile Neutropenia Seven Major Market Analysis

14. Attribute Analysis

15. Febrile Neutropenia Market Outlook (7 major markets)

16. Febrile Neutropenia Access and Reimbursement Overview

17. KOL Views on the Febrile Neutropenia Market.

18. Febrile Neutropenia Market Drivers

19. Febrile Neutropenia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/febrile-neutropenia-market

 

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Blood and Fluid Warming Medical Devices Market
“Blood and Fluid Warming Medical Devices Market” research report provide comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for Blood and Fluid Warming Medical Devices. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Blood and Fluid Warming Medical Devices market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Categories